Overall, the research suggests that maintaining healthy sleep habits, consistent eating patterns and good gut health may help support normal GLP-1 secretion and improve metabolic health
In clinical trials, patients on the highest dose lost an average of around 15% of their body weight over 68 weeks a result that at the time of its approval in 2021, was unlike anything seen in prescription weight loss before
Body composition analyses from clinical studies reveal that weight loss with tirzepatide consists predominantly of fat mass reduction, with relative preservation of lean body mass compared to the proportion typically lost with diet-induced weight loss alone
This can lead to some side effects, especially gastrointestinal ones
However, with such a small sample size, this study is not enough for postpartum GLP-1 use to be considered safe
Pierce PE, Thompson JF, Likowsky WH, et al